Study on Safe and Effective Clinical Methods for Arsenic-containing Compound Qinghuang Powder in Treatment of Myelodysplastic Syndrome
10.3969/j.issn.1005-5304.2017.10.006
- VernacularTitle:含砷中药复方青黄散安全有效治疗骨髓增生异常综合征方法研究
- Author:
Zhongyang DENG
;
Su FANG
;
Hongzhi WANG
;
Xiaoqing GUO
;
Xiupeng YANG
;
Rou MA
;
Yonggang XU
;
Xiaohong YANG
;
Pan ZHAO
;
Mingjing WANG
;
Bowen YI
;
Xiaohong SHANG
;
Xiaomei HU
- Keywords:
myelodysplastic syndrome;
realgar;
arsenic;
safety
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2017;24(10):22-26
- CountryChina
- Language:Chinese
-
Abstract:
Objective To search for application ways for the safe and effective clinical methods of arsenic-containing Compound Qinghuang Powder (Compound QHP) for the treatment of myelodysplastic syndrome (MDS). Methods Totally 200 patients with MDS were included in the study and treated with Compound QHP. After one-month treatment, the 60 patients with the blood arsenic concentrations <20 μg/L were randomly divided into control group and treatment group, with 30 cases in each group. Control group was given stable treatment, while the treatment group was given increased dose of realgar; blood arsenic concentration was detected monthly; realgar 0.1 g was increased each time until blood arsenic concentrations ≥20 μg/L and realgar ≤0.3 g/d. The blood arsenic concentration, clinical efficacy and safety in the two groups were observed. Results Totally 24 cases in each group were included for evaluation finally. The average blood arsenic concentration of treatment group was significantly higher than those of control group (P<0.05). The rate of hematologic improvement was significantly higher in treatment group (54.2％, 13/24) than that in control group (29.2％, 7/24) , with significant difference (P<0.05). The Hb, ANC, and PLT significantly increased in treatment group after treatment (P<0.05). There was no significant difference of incidence rate of adverse reaction observed between treatment group and control group (P>0.05). Conclusion In application of Compound QHP, the blood arsenic concentration can be monitored to adjust the daily dose of realgar, thus to increase the effective blood arsenic concentration, and then improving efficacy without increasing the clinical toxicity.
